AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-7.28%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.09B
AUM Growth
+$2.09B
(-13%)
Cap. Flow
+$264M
Cap. Flow
% of AUM
12.61%
Top 10 Holdings %
Top 10 Hldgs %
53.53%
Holding
115
New
19
Increased
31
Reduced
8
Closed
12
Top Buys
| 1 |
uniQure
QURE
|
$54.6M |
| 2 |
Black Diamond Therapeutics
BDTX
|
$42.3M |
| 3 |
Schrodinger
SDGR
|
$38.7M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$27M |
| 5 |
PayPal
PYPL
|
$23M |
Top Sells
| 1 |
Moderna
MRNA
|
$48.1M |
| 2 |
BioNTech
BNTX
|
$23.4M |
| 3 |
Xencor
XNCR
|
$18.9M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$11M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$10.2M |
Sector Composition
| 1 | Healthcare | 78.33% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Financials | 2.02% |
| 4 | Technology | 1.61% |
| 5 | Communication Services | 1.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gossamer Bio
GOSS
$587M
| $18.4M | 0.78% |
1,808,968
+200,000
| +12% | +$2.03M |
|
|
RUBY
27
DELISTED
Rubius Therapeutics, Inc
RUBY
| $17.3M | 0.73% |
3,883,791
+1,050,000
| +37% | +$4.67M |
|
28
Arrowhead Research
ARWR
$3.84B
| $17.3M | 0.73% |
+600,000
| New | +$17.3M |
|
29
BridgeBio Pharma
BBIO
$9.91B
| $16M | 0.67% |
550,000
+350,000
| +175% | +$10.2M |
|
|
PRNB
30
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $14.8M | 0.63% |
+250,000
| New | +$14.8M |
|
31
Agios Pharmaceuticals
AGIO
$2.36B
| $14.2M | 0.6% |
400,000
-200,000
| -33% | -$7.1M |
|
|
HARP
32
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $13.9M | 0.59% |
120,000
+35,000
| +41% | +$4.05M |
|
|
VNET
33
VNET Group
VNET
$2.15B
| $13.9M | 0.59% |
+1,000,000
| New | +$13.9M |
|
|
TPTX
34
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $13.4M | 0.57% |
300,000
| – | – |
|
35
Ascendis Pharma
ASND
$12.1B
| $11.3M | 0.48% |
100,000
| – | – |
|
36
Uber
UBER
$194B
| $11.2M | 0.47% |
400,000
-100,000
| -20% | -$2.79M |
|
37
Trip.com Group
TCOM
$46.6B
| $10.9M | 0.46% |
+465,000
| New | +$10.9M |
|
38
Aurinia Pharmaceuticals
AUPH
$1.58B
| $10.9M | 0.46% |
+750,000
| New | +$10.9M |
|
39
Y-mAbs Therapeutics
YMAB
$390M
| $10.4M | 0.44% |
400,000
| – | – |
|
|
SAGE
40
DELISTED
Sage Therapeutics
SAGE
| $10.1M | 0.42% |
350,000
+200,000
| +133% | +$5.74M |
|
41
TG Therapeutics
TGTX
$5.03B
| $9.84M | 0.42% |
1,000,000
+350,000
| +54% | +$3.44M |
|
|
ALBO
42
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $9.63M | 0.41% |
588,125
+137,925
| +31% | +$2.26M |
|
|
SWTX
43
DELISTED
SpringWorks Therapeutics
SWTX
| $9.45M | 0.4% |
350,000
| – | – |
|
44
Denali Therapeutics
DNLI
$2.24B
| $8.76M | 0.37% |
500,000
+100,000
| +25% | +$1.75M |
|
45
StoneCo
STNE
$4.38B
| $8.71M | 0.37% |
400,000
| – | – |
|
|
ARAV
46
DELISTED
Aravive, Inc. Common Stock
ARAV
| $8.35M | 0.35% |
1,450,000
+100,000
| +7% | +$576K |
|
47
Cartesian Therapeutics
RNAC
$267M
| $8.23M | 0.35% |
113,788
| – | – |
|
48
Regenxbio
RGNX
$498M
| $8.1M | 0.34% |
250,000
+105,000
| +72% | +$3.4M |
|
|
TCDA
49
DELISTED
Tricida, Inc. Common Stock
TCDA
| $7.92M | 0.33% |
360,000
| – | – |
|
50
ProQR Therapeutics
PRQR
$256M
| $7.14M | 0.3% |
1,300,000
| – | – |
|